Pancreatic cancer is an aggressive disease often detected late because early stages rarely cause specific symptoms. Most tumors arise from exocrine cells, particularly pancreatic ductal adenocarcinoma, while a minority come from hormone‑producing endocrine cells. Key risk factors include age, smoking, chronic pancreatitis, type 2 diabetes, obesity, certain genetic syndromes, and family history.

Research shows that symptoms such as abdominal or back pain, jaundice, weight loss, loss of appetite, nausea, and new‑onset or worsening diabetes tend to appear only when the cancer is advanced. This delay in diagnosis is a major reason for the poor prognosis. Imaging techniques like CT, MRI, endoscopic ultrasound, and PET scans, together with biopsy and blood tests such as CA 19‑9, are used to diagnose and stage the disease, but there is still no reliable screening test for the general population.

Surgical removal of the tumor offers the best chance of long term survival, yet only a minority of patients are eligible at diagnosis. Standard treatments include surgery, chemotherapy, radiotherapy, and increasingly targeted therapies and immunotherapies guided by molecular profiling of the tumor. Researchers are studying mutations in genes such as KRAS, TP53, CDKN2A, and SMAD4, as well as pathways that support tumor growth and spread, to identify new drug targets.

Current research also focuses on blood and stool biomarkers, advanced imaging, and genetic risk scores to enable earlier detection, along with combination treatments that may improve survival and quality of life for patients with advanced disease.